

## SCIENTIFIC ADVISORY BOARD

LCFA has brought together a blue ribbon Scientific Advisory Board comprised of the leading lung cancer clinicians and researchers in the country. Their role is to ensure that LCFA supports and funds the leading edge of lung cancer research based on LCFA's mission statement. In addition, the Scientific Advisory Board members serve as media resources on behalf of LCFA providing informed analysis of medical and technical lung cancer issues in the news. Members of our Scientific Advisory Board include:

### **DR. DENISE ABERLE, M.D.**



***Dr. Ronald Reagan UCLA Medical Center  
UCLA Medical Center, Santa Monica***

Dr. Aberle is a professor of Radiology in the School of Medicine and professor of Bioengineering in the Henry Samueli School of Engineering and Applied Sciences. She is board-certified in both Internal Medicine and Diagnostic Radiology.

Aberle earned her MD degree in 1979 at the University of Kansas in Kansas City, KS and completed a residency in Internal Medicine at Boston University Medical School in 1982. She completed a residency in Diagnostic Radiology at UCLA in 1982, and subspecialty training in thoracic imaging at the University of California, San Francisco.

She has been on faculty in Radiological Sciences since 1987, and was the Section Chief of Thoracic Imaging from 1988 to 2005.

Dr. Aberle is the Vice Chair of Research in Radiological Sciences and a faculty member in the interdisciplinary Biomedical Physics and the Medical Imaging Informatics training programs, both sponsored by the National Institutes of Health.

Dr. Aberle is currently the national Principal Investigator of the ACRIN-NLST (American College of Radiology Imaging Network component of the National Lung Screening Trial). The NLST is an NCI-sponsored randomized controlled trial to compare the efficacy of low dose helical CT versus chest radiography for lung cancer screening. The NLST is the joint collaboration of ACRIN and the Lung Screening Study.

Her research also centers on lung cancer and oncologic imaging for response assessment; quantitative image analysis, and oncology informatics.

## **JULIE R. BRAHMER, MD**



***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
Director, Thoracic Oncology Program Associate Professor of Oncology  
Interim***

***Co-Director, Upper Aerodigestive (UAD) Program***

***Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview***

Julie R. Brahmer, MD, is a global thought leader in the emerging field of immunotherapy. Dr. Brahmer is Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Dr. Brahmer's research and clinical practice focuses on the development of new therapies, including immunotherapies, for the treatment and prevention of lung cancer and mesothelioma. She was involved in the phase 1 trial of the PD-1 blocking antibody, nivolumab. Dr. Brahmer is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee.

## **DR. DAVID CARBONE, M.D., PH.D.**



***Professor of Medicine in the Division of Medical Oncology, The Ohio State University – James Cancer Hospital and Solove Research Institute***

David Carbone graduated summa cum laude from Amherst College in 1977 and received an MD and a PhD in Molecular Biology and Genetics at Johns Hopkins University in 1985. He then did an Internal Medicine internship and residency at The Johns Hopkins Hospital through 1988 followed by a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. In 1991 he was appointed Assistant Professor at the University of Texas Southwestern Medical Center and was promoted to Associate Professor with tenure in 1995. He was recruited to Vanderbilt University in 1996 where he was promoted to full Professor in 1998. He

served as Professor of Medicine, Cell Biology, and Cancer Biology at the Vanderbilt University Medical Center and Director of the Experimental Therapeutics Program and the Thoracic Oncology Center at the Vanderbilt-Ingram Cancer Center. He was also Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer and the Strategic Partnering to Evaluate Cancer Signatures UO1 consortium. In 2012, Dr. Carbone joined Ohio State's Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. He is a professor in the Division of Medical Oncology and will be developing and leading a new thoracic oncology center. The thoracic oncology center will bring physicians and scientists together to develop new and targeted approaches to treating and curing lung cancer. Dr. Carbone's research interests, grant support and publications have been focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy. Recent research directions include molecular profiling of lung cancers and preneoplasias, especially the use of mass spectrometry-based

proteomics. He has over 150 peer-reviewed publications and review articles, has served on several NCI grant review panels, including the clinical program project parent committee, and has continuous NCI funding since early in his career. He has served on organizing committees for both ASCO and AACR and is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and currently serves on the Board of Scientific Counselors for the NCI.

## **JESSICA DONINGTON, M. D.**



***General Thoracic Surgeon and Associate Professor of Cardiothoracic Surgery at NYU School of Medicine***

***Director of the NYU Thoracic Oncology Translational Laboratory***

***Chief of General Thoracic Surgery at Bellevue Hospital***

Dr. Donington is a General Thoracic Surgeon and Associate Professor of Cardiothoracic Surgery at NYU School of Medicine. She is the director of the NYU Thoracic Oncology Translational Laboratory and chief of General Thoracic Surgery at Bellevue Hospital.

She obtained her bachelor degree from the University of Michigan in 1987 and her medical degree from Rush University in Chicago. She completed her general surgery training at Georgetown University and cardiothoracic training at the Mayo Clinic. She also completed a fellowship in the Surgical Branch of the National Cancer Institute in Bethesda. She was on the faculty at Stanford University in the Division of Thoracic Surgery prior to accepting her current position at NYU.

Her clinical and interests focus on the early diagnosis and treatment of non-small cell lung cancer. Areas of expertise include the use of multimodality therapy for thoracic malignancies, treatment options for high risk patients with early stage lung cancer and lung cancer in women. She is the surgical chair for the thoracic oncology section of NRG Oncology Group.

## **DR. STEVEN M. DUBINETT, M.D.**



***Professor of Medicine and Pathology, Director, UCLA Lung Cancer Research Program in the Jonsson Comprehensive Cancer Center***

***Chief, Division of Pulmonary and Critical Care Medicine, and Principal Investigator for the UCLA Lung Cancer SPORE***

Dr. Steven Dubinett has extensive experience in academic investigation, administration, mentorship and peer review. He has received federal peer reviewed funding for translational lung cancer research for the past 20 years. Dr. Dubinett is nationally recognized for translational research in the immunobiology of lung cancer. Building on original discoveries regarding the role of inflammation in the pathogenesis of lung cancer he has developed a translational research program, which now utilizes these laboratory-based discoveries in the clinical setting. He has been involved in mentoring trainees at all levels in a peer-review funded,

translational research program. Twenty of the 23 post-doctoral fellows from his research program are currently continuing in either academic or industry research careers. He has been active both within the training programs in the UCLA academic community and, nationally, in setting policy as a member of foundation and NIH training committees on training. He recently served on the NCI Translational Research Working Group and has served as a mentor for the American Association for Cancer Research grant writing workshop for the past seven years.

He has served on numerous study sections and special emphasis panels for the NIH including chair of the study section for the Lung SPOREs, reviewer for PO1s, the EDRN, Clinical Oncology and Tumor Microenvironment study sections and site review teams for the NCI intramural programs. Dr. Dubinett serves on numerous committees for professional societies including the ASCO Education Committee, the AACR – Cancer Epidemiology and Prevention Awards Selection Committee, the ATS Clinical Problems Program Committee and the organizing committee for the IASLC World Conference on Lung Cancer. He currently serves on the External Advisory Boards (EABs) for the Lung Cancer SPOREs at Colorado and Vanderbilt and the mesothelioma PO1 at the University of Pennsylvania. He served as a member of the NCI TRWG. He has received competitive awards for lung cancer research including the Cecile Lehman Mayer Research Award, the Helen Neufeld Award and the Career Investigator Award from the American Lung Association. In 2008 Dr. Dubinett received the American Thoracic Society Award for Scientific Achievement. He was the Scientific Program Chairperson for the Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research.

## **MARTIN EDELMAN, M.D.**



***Cancer Professor of Medicine***

***Cancer (Primary Specialty)***

***Hematology/Oncology Thoracic Oncology***

Dr. Edelman is the Head of the Section of Solid Tumor Oncology and Associate Director of the Division of Hematology/Oncology for the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

Dr. Edelman received his medical degree from the Albany Medical College and performed his internship and residency in Internal Medicine and Fellowship in Hematology and Oncology at the Naval Medical Center San Diego. After leaving active military service, Dr. Edelman joined the faculty at the University of California, Davis and the VA Northern California Health Care System in 1990. While at UC Davis he was co-director of the thoracic oncology program and developed several trials in lung cancer.

Dr. Edelman was a member of the Lung Cancer committee of the Southwest Oncology Group (SWOG) and chaired two SWOG Phase II trials in lung cancer, both based upon pilot studies performed at UC Davis. From 1999 to 2013, Dr. Edelman was at the University of Maryland Greenebaum Cancer Center in Baltimore. He went to the University of New Mexico from 2013-2014 and then returned to the University of Maryland. Currently, he is a member of the Respiratory Core Committee of the Alliance (CALGB) and is medical oncology co-chair for the Lung Cancer Steering Committee for NRG (RTOG). He leads trials in lung cancer in the Alliance and NRG.

Dr. Edelman is a member of the Thoracic Malignancies Steering Committee of the National Cancer Institute, and Chair of the Integration Panel for the Congressionally Mandated Research Program within DOD for lung cancer. He has also served as a member of the NIH subcommittee H, the ASCO program, education and governmental affairs committees and several NIH study sections.

Internationally, he is the Chair of the Career Development Committee of the International Association for the Study of Lung Cancer and a member of the Chest Tumors faculty for the European Society of Medical Oncology. He is an Associate Editor of the journal "Lung Cancer" and has published over 145 peer reviewed papers in the field.

## **DR. BRUCE E. JOHNSON, M.D.**

***Chief Clinical Research Officer at Dana-Farber Cancer Institute***

***Physician, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital***



***Professor of Medicine at Harvard Medical School***

Bruce E. Johnson, MD is the Chief Clinical Research Officer at Dana-Farber Cancer Institute, Physician in the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, and Professor of Medicine at Harvard Medical School. He is the leader of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program and the Principal Investigator of the DF/HCC Specialized Program of Research Excellence (SPORE) in Lung Cancer. His laboratory-based research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies.

Dr. Johnson is a member of the American Association of Physicians. He served on the American Society of Clinical Oncology (ASCO) Board of Directors from 2008-2011, received the ASCO Cancer Foundation's Translational Research Professorship in 2008, and was selected as a Fellow of the American Society of Clinical Oncology in 2012. He also was awarded the International Association for the Study of Lung Cancer (IASLC) 2010 Scientific Award, given to an IASLC scientist for "lifetime scientific contribution in thoracic malignancy research and who has also contributed to the organization's development." He was one of the leaders of the team awarded the American Association for Cancer Research (AACR) 2010 Team Science Award that "recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention, or treatment of cancer."

Dr. Johnson received his Doctor of Medicine from the University of Minnesota, did postgraduate training at the University of Chicago and the National Cancer Institute, and came to the Lowe Center in 1998 after serving for six years as the head of the Lung Cancer Biology section of the National Cancer Institute's Medicine Branch.

## **DR. DAVID H. JOHNSON, M.D.**



***Chair: Lung Cancer Foundation of America Scientific Advisory Board***

***Donald W. Seldin Distinguished Chair in Internal Medicine at UT Southwestern Medical Center in Dallas, Texas***

***Chairman of the Department of Internal Medicine at UT Southwestern Medical Center in Dallas, Texas***

Dr. David H. Johnson is the Donald W. Seldin Distinguished Chair in Internal Medicine and Chairman of the Department of Internal Medicine at UT Southwestern Medical Center in Dallas, Texas. He is a board certified medical oncologist who specializes in experimental therapeutics and the treatment of lung cancers. From 1983 to 2010 he was a member of the faculty at the Vanderbilt University Medical School where he held the Cornelius A. Craig Chair of Medical and Surgical Oncology and served as the Director of the Division of Hematology and Medical Oncology and Deputy Director of the Vanderbilt-Ingram Cancer Center of which he was a founding member. In 2010 he relocated to Dallas Texas to assume his current position.

In 2004-2005 Dr. Johnson served as the President of the American Society of Clinical Oncology (ASCO) during which time he worked to advance ASCO's cancer survivorship and quality care initiatives. From 2005-2009 he was a member of the International Association for the Study of Lung Cancer (IASLC) Board of Directors. Additional past activities include Chairman of the American Board of Internal Medicine (ABIM) Board of Directors, Chairman of the ABIM Medical Oncology Subspecialty Board, Chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group, member of the FDA's Oncology Drug Advisory Committee and service on the Boards of Directors of the National Comprehensive Cancer Network and the LiveSTRONG Foundation. He has authored more than 400 journal articles and 40 book chapters and edited four oncology textbooks.

Dr. Johnson is an elected member of the Association of American Physicians, a Master of the American College of Physicians and the recipient of Established Investigator Award from the Cancer Research and Prevention Institute of Texas. In 2016 he received the Distinguished Achievement Award from the American Society of Clinical Oncology. He earned his medical degree from the Medical College of Georgia and received his Medical Oncology training at Vanderbilt University.

## **NATASHA B LEIGHL, M.D.**



***Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre***

Natasha Leighl is a medical oncologist at the Princess Margaret Hospital, Toronto, Canada, and Associate Professor in the Department of Medicine at the University of Toronto, Toronto, Canada.

After receiving her MD from the University of Toronto, Dr Leighl completed

residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr Frances Shepherd at the Princess Margaret Hospital, a Fellowship in Clinical Oncology with Professor Martin Tattersall at the University of Sydney, Australia, and received her MMSc in Clinical Epidemiology at the University of Newcastle, Australia.

Dr Leighl's main interest is in developing new treatments in lung cancer. She is a member of the Lung Disease Site Executive and co-chairs the Committee on Economic Analysis in the NCIC Clinical Trials Group. Dr Leighl is currently Web Editor of the Journal of Thoracic Oncology, Section Co-Editor of The Oncologist and Current Oncology and a member of the editorial board of the Journal of Clinical Oncology. She has served on several committees including as Lung Track Leader for the American Society of Clinical Oncology (ASCO) Cancer Education Committee, the Royal College of Physicians and Surgeons of Canada Medical Oncology Examination Board and the International Association for the Study of Lung Cancer (IASLC) Career Development and Continuing Education Committees. She is currently President of Lung Cancer Canada and has recently been awarded the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at the University Health Network, University of Toronto.

## **DR. MICHAEL WEITZ, M.D.**



***Associate Director Emergency Services, Saint Johns Health Center***

***Assistant Clinical Professor of Medicine, Olive View UCLA Medical Center***

***Lung Cancer Survivor***

Michael Weitz graduated from USC in 1980 and received his M.D. from The Chicago Medical School in 1984. He did 2 post graduate years at Cedars-Sinai in Los Angeles, one each in Internal Medicine and General Surgery before completing the UCLA Emergency Medicine Residency Program in 1990. He became Assistant Professor of Medicine at UCLA and a part time faculty member in the Department of Emergency Medicine at UCLA/ Olive View Medical Center. He won the prestigious Golden Olive Award for excellence in teaching for three consecutive years. He has been the Associate Director of the Emergency Department at Saint John's Health Center in Santa Monica, California since 1994. Michael is a lung cancer advocate and is himself a lung cancer survivor since 2006.